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Sclerotic chronic graft-versus-host disease (sclGVHD) is associated with signiﬁcant morbidity and a poor
quality of life. We reviewed 502 patients diagnosed with chronic GVHD and analyzed the incidence and risk
factors of sclGVHD and long-term outcomes and immunosuppressive therapy (IST) cessation in patients with
sclGVHD. With a median onset at 18 months the cumulative incidence of sclGVHD was estimated at 22.6% at
5 years (95% conﬁdence interval, 18.6% to 26.8%). Univariate and multivariate analysis identiﬁed 2 risk factors
for sclGVHD: non-T cell depletion (hazard ratio [HR] 9.09, P < .001) and peripheral blood stem cell (HR 3.87,
P < .001). Overall survival (OS) at 5 years was signiﬁcantly better in the sclGVHD group (88.1%) compared with
the non-sclGVHD group (62.7%; P < .001), as were nonrelapse mortality (7.3% versus 21.5% at 5 years) and
relapse rates (9.1% versus 19.3% at 5 years). There was no difference in the rate of IST cessation at 5 years
(44.8% versus 49.9%, P ¼ .312), but there was a trend of longer IST duration in the sclGVHD group compared
with the non-sclGVHD group (median 71.6 months versus 62.9 months). In conclusion, T cell depletion and
graft source affect the risk of sclGVHD. SclGVHD did not adversely affect long-term outcomes or IST duration.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a signiﬁcant
cause of morbidity andmortality of allogeneic hematopoietic
cell transplantation (allo-HCT), resulting in a higher risk of
late nonrelapse mortality (NRM) and poor quality of life [1,2].
The National Institutes of Health (NIH) proposed consensus
criteria for the diagnosis and staging of cGVHD based
on clinical manifestations, which are now widely used in
clinical practice [3]. These criteria identify sclerotic cGVHD
(sclGVHD) as a distinctive phenotype of cGVHDwith sclerotic
features in the skin characterized by thickened, tight, and
fragile skin [3]. SclGVHD includes several cutaneous pre-
sentations resembling morphea, systemic sclerosis, or
eosinophilic fasciitis [4].dgments on page 1757.
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ty for Blood and Marrow Transplantation.SclGVHD may cause signiﬁcant morbidity and disability
because it is often associated with poor wound healing,
inadequate lymphatic drainage, skin ulcers from minor
trauma, and joint contractures, but there are only a few
studies that described its clinicopathological features and
risk factors [4-8]. The incidence of sclGVHD has been re-
ported to be 15% to 20% among patients with cGVHD [5,7,8],
and a large cross-sectional study of single-patient visits for
the evaluation of severe cGVHD reported it to be as high as
53% [4]. Because sclGVHD usually occurs late in the course of
cGVHD, it may result in the need for prolonged systemic
immunosuppressive therapy (IST) with multiple agents
[4,5,7] and consequently adversely affect long-term out-
comes [4,8]. However, because long-term outcomes of
sclGVHD have not been investigated recently, the question of
whether sclGVHD patients have an adverse prognosis with
higher mortality has not been answered. Therefore, we
conducted an institutional retrospective study of patients
who developed cGVHD to analyze the incidence, clinical risk
factors of sclGVHD, long-term outcomes, IST treatment fail-
ure, and IST cessation rates in patients who developed
sclGVHD.
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We reviewed 502 consecutive patients diagnosed with cGVHD between
January 2000 and October 2012 at the Princess Margaret Cancer Centre,
Toronto, Canada. We reclassiﬁed cGVHD according to the NIH consensus
criteria [3], particularly with respect to the date of onset of cGVHD, involved
organs, the severity of cGVHD, ISTs for the treatment of cGVHD, and the
cessation of ISTs. The research ethics board at the University Health Network
approved this study.
In the 502 patients, median time of onset was 4.8 months after allo-HCT
(range, 2.1 to 48.8). Ninety-six patients (19.1%) were diagnosed with
sclGVHD. There were 358 survivors with a median follow-up time of
60.7 months (range, 2.7 to 159.1). Patient and transplant-related charac-
teristics are summarized in Table 1.
Deﬁnition of sclGVHD
SclGVHD was deﬁned as sclerodermatous skin lesions with either
deep or superﬁcial sclerotic features on physical examination, fasciitis
demonstrated on magnetic resonance image, or joint contracture on phys-
ical examination documented in medical records as previously described
[3,5]. The overall severity of cGVHD and the severity of organ-speciﬁc
cGVHD (skin, mouth, eyes, gastrointestinal tract, liver, lungs, joints and
fascia, and the female genital tract) were graded using the NIH consensus
criteria [3].
Transplant Procedures
For related donors, HLA-A, -B, and -DR were screened, and for unrelated
donors HLA-C and -DQ were added. Unrelated donors of peripheral bloodTable 1
Patient, Disease, and Transplant Characteristics
cGVHD (n ¼ 502)
Median age at the transplant, yr (range) 48 (18-70)
Gender, no. (%)
Male 291 (58)
Female 211 (42)
Gender mismatch, no. (%)
Male to male 134 (27)
Male to female 89 (18)
Female to male 115 (23)
Female to female 93 (19)
Missing 71 (14)
Disease, no. (%)
AML 199 (40)
ALL 50 (10)
Acute leukemia 5 (1)
MDS 48 (10)
CML 55 (11)
MF/MPD 34 (7)
CLL 31 (6)
Malignant lymphoma 63 (13)
AA 14 (3)
Others 3 (1)
Intensity of conditioning regimen, no. (%)
Myeloablative 358 (71)
Nonmyeloablative 144 (29)
HLA and donor type, no. (%)
Related 345 (69)
Matched unrelated 134 (27)
Mismatched unrelated 23 (5)
Stem cell source, no. (%)
Bone marrow 102 (20)
Peripheral blood 400 (80)
TCD, no. (%)
Depleted 86 (17)
Not depleted 416 (83)
TBI in conditioning, no. (%)
None 106 (21)
400 cGy 215 (43)
>400 cGy 181 (36)
GVHD prophylaxis, no. (%)
CyA/MTX  TCD 235 (47)
CyA/MMF  TCD 195 (39)
CyA/TCD 63 (13)
Others 9 (2)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MD
myeloﬁbrosis; MPD, myeloproliferative disorder; CLL, chronic lymphocytic leukem
methotrexate; MMF, mycophenolate mofetil or mycophenolate sodium.stem cells (PBSCs) or bone marrow cells were identiﬁed through the One-
Match Stem Cell and Marrow Donor Network.
Patients received conditioning regimens before HCT infusion as per
institutional protocols [9,10]. Related donor transplants were not T cell
depleted (TCD), but unrelated donor transplants were TCD in vivo using
alemtuzumab. GVHD prophylaxis consisted of cyclosporine (administered
for 3 months in related donor transplants unless GVHD required further
treatment and for 6 months in unrelated donor transplants), combined with
either methotrexate (15 mg/m2 on day þ1 and 10 mg/m2 on days þ3, þ6,
and þ11 after allo-HCT) or mycophenolate mofetil (15 mg/kg every 8 hours
until day þ30) [9].
The ﬁrst line treatment for acute GVHD (aGVHD) included oral predni-
sone or intravenous methylprednisolone (equivalent to 2 mg/kg/day of
methylprednisolone). The treatment of cGVHD was decided after consid-
ering the individual patient’s clinical status and IST. Steroid therapy was
used as ﬁrst-line treatment for those already on IST, whereas either steroids,
cyclosporine, or both agents in combinationwere used for patients receiving
IST. When additional treatment was indicated because of resistance to
previous lines of IST, a ﬂare of GVHD, or intolerance, second or further lines
of IST were introduced according to each patient’s clinical manifestations or
toxicity proﬁles. Theses salvage regimens included azathioprine, mycophe-
nolate mofetil, tacrolimus, extracorporeal photopheresis, rituximab, or
combination therapy [11].
Statistics
Overall survival (OS) and GVHD-speciﬁc survival (GSS) were calculated
using the Kaplan-Meier method with a log rank test. OS was deﬁned as datesclGVHD (n ¼ 96) Nonsclerotic (n ¼ 406) P
45 (19-68) 49 (18-70)
51 (53) 240 (59) .302
45 (47) 166 (41)
23 (24) 111 (27) .357
16 (17) 73 (18)
21 (22) 94 (23)
25 (26) 68 (17)
11 (12) 60 (15)
27 (28) 172 (42) .006
14 (15) 36 (9)
0 (0) 5 (4)
12 (13) 36 (9)
14 (15) 41 (10)
4 (4) 30 (7)
13 (14) 18 (4)
10 (10) 53 (13)
2 (2) 12 (3)
0 (0) 3 (1)
74 (77) 284 (70) .209
22 (23) 122 (30)
78 (81) 267 (66) .001
18 (19) 116 (29)
0 (0) 23 (6)
10 (10) 92 (23) .007
86 (90) 314 (77)
3 (3) 83 (20) <.001
93 (97) 323 (80)
19 (20) 87 (21) .010
30 (31) 185 (46)
47 (49) 134 (33)
61 (64) 174 (43) <.001
31 (32) 164 (40)
2 (2) 61 (15)
2 (2) 7 (2)
S, myelodysplastic syndrome; CML, chronic myelogenous leukemia; MF,
ia; AA, aplastic anemia; TBI, total body irradiation; CyA, cyclosporine; MTX,
Table 2
Characteristics of NIH cGVHD in Patients with Sclerotic and Nonsclerotic
Manifestations
cGVHD
Cohort
(n ¼ 502)
sclGVHD
(n ¼ 96)
Non-sclGVHD
(n ¼ 406)
P
Classiﬁcation of cGVHD at initial diagnosis of cGVHD
Classical cGVHD 219 (44) 38 (40) 181 (45) .611
Overlapping
syndrome
283 (56) 58 (60) 225 (55)
Organ-speciﬁc cGVHD at the initiation of systemic treatment for cGVHD
Skin 381 (76) 78 (87) 303 (74) .008
Liver 374 (75) 71 (79) 303 (74) .291
Mouth 323 (65) 71 (79) 252 (61) .001
Eyes 215 (43) 43 (48) 172 (42) .294
Gastrointestinal
tract
146 (29) 33 (37) 113 (27) .080
Lung 138 (28) 28 (31) 110 (27) .395
Genitourinary
organs
49 (10) 12 (13) 37 (9) .207
Global scoring of cGVHD at initial diagnosis of cGVHD
Mild grade 205 (41) 31 (32) 174 (43) .107
Moderate grade 230 (46) 53 (55) 177 (44)
Severe grade 67 (13) 12 (13) 55 (14)
Values are total number of cases, with percents in parentheses.
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deﬁned as the date diagnostic signs and symptoms were ﬁrst documented
or the date a pathological diagnosis was made, whichever occurred earlier. If
patients developed sclGVHD within 30 days after the ﬁrst presentation of
cGVHD, they were considered to have developed sclGVHD as the ﬁrst
manifestation of cGVHD. GSS was deﬁned from the date cGVHD was ﬁrst
documented to the date of death from cGVHD-speciﬁc causes, including
cGVHD itself, infection associated IST, or both, and deaths from other causes
were censored.
Transplant-related characteristics were analyzed to compare the dif-
ferences between the sclGVHD and non-sclGVHD groups using Pearson’s
chi-square or Fisher’s exact tests. The cumulative incidences of sclGVHD,
nonrelapsemortality (NRM), disease relapse, the cessation of IST, and failure
of frontline treatment for sclGVHD were estimated considering competing
risks. The cessation of IST was deﬁned as the discontinuation of systemic
glucocorticosteroids, calcineurin inhibitors, azathioprine, mycophenolate,
extracorporeal photopheresis, and/or rituximab. Anti-inﬂammatory medi-
cations such as clarithromycin for lung GVHD, ursodeoxycholic acid for liver
GVHD, topical steroids, and inhaled steroids were not considered as sys-
temic IST.
Failure of frontline IST for sclGVHD was deﬁned as the initiation of the
next line of IST for cGVHD regardless of the target organs. The next line of IST
for cGVHD included either a change of systemic IST, the addition of another
agent (either systemic IST or hydroxychloroquine), or a re-escalation of the
dose of prednisone to 1 mg/kg/day. Disease relapse and NRM were
competing risks for sclGVHD, the cessation of IST, and failure of IST. NRMwas
a competing risk fordisease relapse andvice versa. Theunivariate analysis for
incidence with competing risks was performed using Gray’s method.
The time-dependent Cox proportional hazard regression model was
used for multivariate analysis of OS and GSS with sclGVHD as a time-
dependent covariate. The multivariate analysis for the cumulative in-
cidences of sclGVHD, NRM, and disease relapse was performed using
Fine-Gray proportional hazard regression with competing events. The
stepwise selection algorithm was applied for model selection using the
criteria for variable selection, P¼ .1 for variable entry and P¼ .05 for variable
removal. When P < .05, the variable was considered statistically signiﬁcant.
All statistical analyses were performed using EZR software (Saitama
Medical Center, Jichi Medical University, Saitama, Japan) [12]. EZR is a
modiﬁed version of R commander (version 1.8-4; http://www.jichi.ac.jp/
saitama-sct/SaitamaHP.ﬁles/statmedEN.html).
RESULTS
Incidence and Clinical Manifestations of sclGVHD
Cumulative incidence of sclGVHD was 22.6% at 5 years
(95% conﬁdence interval [CI], 18.6 to 26.8; Supplementary
Figure 1). The median time to onset of sclGVHD was
18 months (range, 3.2 to 72.9) in 96 patients diagnosed with
sclGVHD.
Among the 96 patients diagnosed as sclGVHD, themedian
time to the ﬁrst presentation of cGVHD was 5.1 months
(range, 2.3 to 26.5). Only seven patients (7.3%) developed
sclGVHD as the ﬁrst manifestation of cGVHD, whereas the
remaining 89 (92.7%) had previous cGVHD involvement of
other organs.
Of the 96 patients with sclGVHD, 33 (39.6%) were classi-
ﬁed as classical cGVHD according to the NIH consensus
criteria, comparedwith 181 patients (44.5%) in thosewithout
sclGVHD (P ¼ .611; Table 2). Patients with sclGVHD had more
skin and mouth involvement (86.7% and 78.9%, respectively)
compared with the non-sclGVHD group (73.5% and 61.3%,
respectively; Table 2). There was no difference in the global
score of cGVHD at its onset between the sclGVHD and non-
sclGVHD groups (P ¼ .107).
Risk Factors for sclGVHD
There were signiﬁcant differences in transplant-related
characteristics between the sclGVHD and non-sclGVHD
groups, including diagnosis, donor type, stem cell source,
TCD, total body irradiation, GVHD prophylaxis, and prior
aGVHD (Table 1 and Supplementary Table 1). Most patients
with sclGVHD received non-TCD grafts, 96.9% compared with
79.6% in the non-sclGVHD group. In the sclGVHD group,86.5% had a history of aGVHD compared with 76.8% in the
non-sclGVHD group (P ¼ .038; Supplementary Table 1).
Univariate analysis using the log rank test identiﬁed 2 risk
factors for sclGVHD; non-TCD (4.0% in TCD and 25.9% in non-
TCD, P< .001; Figure 1A) and PBSCs (26.5% in PBSC and 10.2%
in bone marrow, P< .001; Figure 1B and Table 3). These were
conﬁrmed on multivariate analysis as independent risk fac-
tors for sclGVHD (non-TCD: hazard ratio [HR] 7.09, P < .001;
PBSCs: HR 2.96, P ¼ .001). In particular, the non-TCD group
showed a 7-fold higher risk of sclGVHD than the TCD group
did. HLA mismatch donor was not associated with an
increased risk of sclGVHD, although it was suggested to be
preventive of sclGVHD in a previous study [5].
Long-Term Outcomes according To the Development of
sclGVHD
OS, NRM, disease relapse rate, and GSS at 5 years were
better in the sclGVHD group: OS 88.1% in sclGVHD versus
62.7% in non-sclGVHD, P< .001; NRM 7.3% in sclGVHD versus
21.5% in non-sclGVHD, P < .001; disease relapse rate 9.1% in
sclGVHD versus 19.3% in non-sclGVHD, P ¼ .018; and GSS
98.4% in sclGVHD versus 78.6% in non-sclGVHD, P < .001
(Table 4). There was no difference in the rate of IST cessation
at 5 years between the sclGVHD and non-sclGVHD groups
(44.8% versus 49.9%, P ¼ .312), although those with sclGVHD
seemed to remain on IST longer than those without sclGVHD
(median 71.6 months versus 62.9 months; Figure 2A). The
stacked incidence curves of NRM, disease relapse, and IST
cessation demonstrated lower incidences of NRM and dis-
ease relapse in the sclGVHD group compared with the non-
sclGVHD group (Figure 2B).
Patients with sclGVHD showed better OS and GSS in the
univariate analysis. To adjust time-dependent effects of
sclGVHD, multivariate analyses for OS and GSS were
performed using Cox’s proportional hazardmodel with time-
dependent covariate of sclGVHD. Time-dependent multi-
variate analysis conﬁrmed that sclGVHD is a favorable factor
with respect to OS (HR .26, 95% CI, .14 to .47, P< .001) and GSS
(HR .08, 95% CI, .02 to .31, P < .001; Table 4). Multivariate
analysis for NRM and disease relapse using Fine-Gray pro-
portional hazard regression with competing events also
veriﬁed that sclGVHDwas a favorable factor for NRM (HR .46,
Figure 1. Cumulative incidence of sclGVHD according to the risk factor, including TCD and source of stem cell. (A) Cumulative incidence of sclGVHD according to TCD:
non-TCD group showed a 7-fold higher risk of sclGVHD compared with the TCD group. (B) Cumulative incidence of sclGVHD according to graft source: PBSCs increase
the risk of sclGVHD 3 times compared with bone marrow (BM).
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CI, .26 to .94, P ¼ .032). In summary, the development of
sclGVHD at least does not seem to affect long-term outcomes
adversely in terms of OS, NRM, disease relapse, and GSS.
Treatment and Outcomes of sclGVHD
With a median follow-up duration of 49 months (range, 2
to 130) after diagnosis of sclGVHD, all 96 patients withTable 3
Univariate and Multivariate Analyses for the Risk Factors in sclGVHD at
5 Years
Risk Factor Univariate Multivariate
Cumulative
Incidence
(95% CI)
P HR (95% CI) P
Age (continuous) .99 (.98-1.01) .44
Gender
Male 20 (16-26) .19
Female 26 (19-32)
Donorerecipient
gender
Female to male 20 (13-29) .45
Others 23 (19-28)
Intensity of conditioning regimen
Myeloablative 23 (19-28) .38
Nonmyeloablative 20 (13-29)
Related donor type
Related 25 (20-30) .07
Unrelated 15 (9-22)
Mismatched donor
Matched 23 (19-28) .21
Mismatched NA
Stem cell source
Bone marrow 10 (5-17) <.001 1 .001
Peripheral blood 27 (22-32) 2.96 (1.52-5.74)
Total body irradiation
400 cGy 20 (15-26) .08
>400 cGy 27 (20-33)
TCD
Depleted 4 (1-10) <.001 1 <.001
Not depleted 26 (21-31) 7.09 (2.25-22.34)
Prior aGVHD 24 (19-29) .20
De novo cGVHD 15 (9-24)
Values for cumulative incidences are percents.sclGVHD received at least 1 line of systemic IST during the
course of their cGVHD (median 3 lines, range 1 to 5). Of 96
patients with sclGVHD, 22 underwent extracorporeal pho-
topheresis and 21 were treated with hydroxychloroquine for
sclGVHD.
With respect to ﬁrst-line treatment for sclGVHD, 63 pa-
tients (66%) were treated with either prednisone alone
(n ¼ 16) or another IST in addition to prednisone (n ¼ 47).
Among the 47 patients treated with prednisone in conjunc-
tion with another IST, 31 (66%) received azathioprine as the
other IST. Seventeen patients (18%) were initially treated
with azathioprine, 14 as a single agent and 3 in combination
with hydroxychloroquine. Two patients were treated with
hydroxychloroquine alone, whereas the remaining 6 patients
were managed with topical agents only because of the
limited involved area of sclerotic lesion. Those 6 patients
treated with topical agents were already on systemic IST but
did not require an escalating dose of systemic IST for
sclGVHD.
Regarding the ﬁrst-line treatment for sclGVHD, the cu-
mulative incidences of sclGVHD treatment failurewere 34.4%
at 6 months (95% CI, 25.0% to 44.0%) and 64.7% at 2 years
(95% CI, 54.0% to 73.6%) with a median time to failure of
10.9 months (Figure 3A). The IST cessation rate at 4 years in
those treated for sclGVHD was 50.1% (95% CI, 37.6% to 61.4%)
with a median time to cessation of 44.5 months (Figure 3B).
DISCUSSION
This study showed that the incidence of sclGVHD among
patients with cGVHD in this study cohort is comparable
(22.6% at 5 years) to previous reports, that PBSCs and non-
TCD were identiﬁed as independent risk factors for
sclGVHD, and that sclGVHD did not adversely affect trans-
plant outcomes and was associated with longer IST duration.
However, the IST cessation rate at 5 years was similar to that
seen in the non-sclGVHD group.
Little is known about the clinical risk factors, clinical
course, or pathogenesis of sclGVHD due to the paucity of
published data. We attempted to address this issue with this
single-institution retrospective study of a relatively large
Table 4
Multivariate Analyses for OS, GSS, NRM, and Disease Relapse
Risk Factor Univariate Multivariate
P HR 95% CI P
OS
Age (continuous) .040 1.016 1.002-1.030 .024
Unrelated .003 1.662 1.169-2.363 .005
Mismatched .007
Female to male .228
PBSC .655
Nonmyeloablative .029
TCD .002
De novo cGVHD .236
Moderate/severe cGVHD* .006 1.811 1.278-2.568 .001
SclGVHDy <.001 .257 .141-.467 <.001
GSS
Age (continuous) .032
Unrelated .012 2.210 1.321-3.698 .003
Mismatched <.001
Female to male <.001 1.632 1.016-2.622 .043
PBSC 1
Nonmyeloablative .818
TCD .004
De novo cGVHD .020 .411 .188-.899 .026
Moderate/severe cGVHD* <.001 4.524 2.376-8.615 <.001
SclGVHDy <.001 .075 .018-.306 <.001
NRM
Age (continuous) .081 1.017 1.001-1.033 .035
Unrelated .018 1.605 1.022-2.522 .040
Mismatched .003 2.195 1.020-4.723 .044
Female to male .013 1.661 1.080-2.554 .021
PBSC .279
Nonmyeloablative .260
TCD .007
De novo cGVHD .177
Moderate/severe cGVHD* <.001 2.696 1.728-4.205 <.001
SclGVHD <.001 .461 .273-.779 .004
Disease relapse
Age (continuous) .048
Unrelated .236
Mismatched .668
Female to male .015 .430 .223-.829 .012
PBSC .972
Nonmyeloablative .010
TCD .618 1.612 1.011-2.571 .045
De novo cGVHD .399
Moderate/severe cGVHD* .039
SclGVHD .013 .493 .259-.940 .032
* Global scoring of cGVHD by NIH consensus criteria at the onset of
cGVHD.
y Time-dependent covariate.
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incidence of sclGVHD comparable with that previously re-
ported (20% at 3 years) [5]. Similarly, our study cohort had an
incidence of sclGVHD as the ﬁrst presentation of cGVHD of
10%, previously reported as approximately 7% [5].
We identiﬁed PBSCs as an independent risk factor for
sclGVHD (Figure 1B), which conﬁrms previous observations
of a higher incidence of sclGVHD in patients receiving a PBSC
graft [5,8]. Inamoto et al. [5] demonstrated HLA-mismatched
donors were associated with a lower risk of sclGVHD; how-
ever, this was not reproducible in this study. Non-TCD grafts
were also identiﬁed as an independent risk factor for
sclGVHD (Figure 1A), but unrelated or mismatched donors
were not. This might be due to a confounding effect because
unrelated donor transplants in this study were TCD.
Furthermore, unlike previous studies, we were not able to
conﬁrm total body irradiation as a risk factor for sclGVHD
[4,5,7].
SclGVHD usually occurs late in the course of cGVHD, with
a median onset of 15 to 16 months [5,8]. This could lead tothe assumption that patients with sclGVHD require longer
periods of systemic IST [5]. Prolonged use of IST can poten-
tially increase the risk of infectious complications, and it has
been suggested that the need for prolonged IST in sclGVHD
might therefore adversely affect long-term outcomes [4,5,7].
Our results conﬁrmed that sclGVHD developed late post-HCT
(median time of onset, 18 months) and that patients who
developed it needed a longer duration of systemic IST (me-
dian duration of 70.5 months versus 62 months in the non-
sclGVHD group). However, the cumulative incidence curves
of IST cessation crossed over after 5 years following allo-HCT.
Also, more than half of the patients in this study were able to
discontinue systemic IST at 7 years with no statistically sig-
niﬁcant difference between the sclGVHD and non-sclGVHD
groups. In this study, the cumulative incidence of frontline
sclGVHD treatment failure at 6 months was 34.4%, which is
comparable with that previously reported (34%) [13]. How-
ever, a previous report demonstrated that only 15% of pa-
tients who received second-line treatment for cGVHD were
able to discontinue IST at 4 years [13], whereas our results
show that 50.1% of the patients with sclGVHD were able to
discontinue IST at 4 years from the initiation of frontline IST
for sclGVHD.
Interestingly, in this study sclGVHD seemed to be favor-
able for OS, NS, disease relapse, and GSS. With the exception
of a small series [7], previous studies reported worse long-
term outcomes with sclGVHD [4,8] or no signiﬁcant impact
on survivals [5]. Our results suggest that sclGVHD could
potentially follow a more benign course than previously
thought, which allows patients with sclGVHD to have a
sustained graft-versus-leukemia effect and therefore better
survival outcomes. Nevertheless, although some cases of
sclGVHD are manageable, this form of cGVHD has a potential
for considerable morbidity and disability. The association of
sclGVHD and transplant outcomes needs to be carefully
reassessed in future studies to validate the ﬁndings from this
study and to shed light on the possible reasons for this
positive effect.
It is important to identify clinical risk factors associated
with sclGVHD to predict its clinical course but also to
further understand its pathogenesis, particularly in relation
to data from animal models. Although there is no compre-
hensive theory for the immunopathogenesis of cGVHD,
immune priming at least in cGVHD murine models is not
dependent on tissue damage from conditioning [14]. This
may explainwhy wewere not able to identify an association
between sclGVHD and a prior history of skin aGVHD in this
study cohort. Murine models of sclGVHD depend on CD4þ
Tcells that release T helper 2 cytokines, which can stimulate
other cells to release ﬁbrosing cytokines (such as IL-13 and
transforming growth factor-b) [15,16], resulting in scle-
rodermatous changes [14,17,18]. Other models have also
shown that cellular mediators secreted by macrophages,
eosinophils, and mast cells can also cause ﬁbroblast pro-
liferation and collagen production [14,19]. A study using a
murine model showed granulocyte colony-stimulating
factoremobilized transplants induced sclGVHD by donor
IL-17A predominantly derived from donor CD8þ T cells [20].
This could possibly explain the underlying pathogenesis of
the increased risk of sclGVHD associated with PBSC grafts.
Data from animal models, although compelling, cannot be
correlated directly to clinical outcomes because murine
models fail to reproduce the full clinical spectrum seen
in humans, which suggests other mechanisms might be
at play.
Figure 2. Cessation of IST patients with sclGVHD. (A) Cumulative incidence of IST cessation of sclGVHD and non-sclGVHD groups. (B) Stacked incidence curves of IST
cessation, NRM, and disease relapse in sclGVHD and non-sclGVHD groups.
Figure 3. Treatment outcomes of frontline IST in patients with sclGVHD. (A) Failure rate of ﬁrst-line treatment for sclGVHD. (B) Cumulative incidence of IST cessation
of sclGVHD.
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J. Uhm et al. / Biol Blood Marrow Transplant 20 (2014) 1751e1757 1757In conclusion, the incidence of sclGVHD is high (>20%)
among patients with cGVHD. PBSCs and non-TCD were
identiﬁed as independent risk factors for sclGVHD. Although
this study suggests that sclGVHD does not affect transplant
outcomes adversely, it still can result in signiﬁcant morbidity
and disability. Further studies are needed to verify the ﬁnd-
ings from this study and to help elucidate the pathogenesis of
sclGVHD.
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